Literature DB >> 28699391

Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells.

Keiichi Torimoto1, Yosuke Okada1, Shingo Nakayamada1, Satoshi Kubo1, Yoshiya Tanaka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28699391     DOI： 10.1089/thy.2017.0062

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  6 in total

Review 1.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 2.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

3.  Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Authors:  Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Wenchao Li; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike-Christian Burandt; Stefan Steurer; Waldemar Wilczak; Andrea Hinsch
Journal:  Dis Markers       Date:  2019-01-10       Impact factor: 3.434

4.  Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimoto's disease and its clinical significance.

Authors:  Ninglei Li; Xiaolong Liu; Luzhe Han; Rui Zhou; Jian Yan; Guoxiang Zhao; Lixin Liu
Journal:  Oncol Lett       Date:  2019-03-20       Impact factor: 2.967

5.  Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.

Authors:  Norio Okada; Shintaro Iwama; Takayuki Okuji; Tomoko Kobayashi; Yoshinori Yasuda; Eri Wada; Takeshi Onoue; Motomitsu Goto; Mariko Sugiyama; Taku Tsunekawa; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Hidetaka Suga; Ryoichi Banno; Tetsunari Hase; Masahiro Morise; Mitsuro Kanda; Kenji Yokota; Naozumi Hashimoto; Masahiko Ando; Yasushi Fujimoto; Masato Nagino; Yasuhiro Kodera; Mitsuhiro Fujishiro; Hideharu Hibi; Michihiko Sone; Hitoshi Kiyoi; Momokazu Gotoh; Yuichi Ando; Masashi Akiyama; Yoshinori Hasegawa; Hiroshi Arima
Journal:  Br J Cancer       Date:  2020-02-03       Impact factor: 7.640

6.  Dynamic follow-up of the effects of programmed death 1 inhibitor treatment on thyroid function and sonographic features in patients with hepatocellular carcinoma.

Authors:  Xiaoya Zheng; Heng Xiao; Jian Long; Qiang Wei; Liping Liu; Liping Zan; Wei Ren
Journal:  Endocr Connect       Date:  2022-05-23       Impact factor: 3.221
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.